https://finviz.com/news/46482/axsome-therapeutics-axsm-reports-q1-loss-tops-revenue-estimates
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Stock screener for investors and traders, financial visualizations.
axsome therapeuticsaxsmreportsq1loss
https://www.dlapiper.com/en-za/news/2023/03/dla-piper-advises-axsome-therapeutics-in-license-agreement-with-pharmanovia
DLA Piper advises Axsome Therapeutics in license agreement with Pharmanovia for commercializing...
DLA Piper advised Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central...
dla piperaxsome therapeutics
https://www.globenewswire.com/news-release/2018/04/26/1487940/0/en/Axsome-Therapeutics-Announces-Positive-Outcome-of-Interim-Analysis-of-STRIDE-1-Phase-3-Trial-of-AXS-05-in-Treatment-Resistant-Depression.html
Axsome Therapeutics Announces Positive Outcome of Interim
Independent Data Monitoring Committee recommends trial continuation Second interim analysis anticipated second half of 2018 for efficacy NEW YORK, April ...
axsome therapeuticspositive outcomeannouncesinterim
https://www.biospace.com/press-releases/axsome-therapeutics-champions-brain-health-during-alzheimers-brain-awareness-month
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month - BioSpace
axsome therapeuticsbrain healthawareness monthchampions
https://www.macrotrends.net/stocks/charts/AXSM/axsome-therapeutics/gross-profit
Axsome Therapeutics Gross Profit 2014-2026 | AXSM | MacroTrends
Axsome Therapeutics annual/quarterly gross profit history and growth rate from 2014 to 2026. Gross profit can be defined as the profit a company makes after...
axsome therapeuticsgross profit20142026axsm
https://www.benzinga.com/insights/analyst-ratings/25/01/43094823/12-analysts-have-this-to-say-about-axsome-therapeutics
12 Analysts Have This To Say About Axsome Therapeutics - Axsome Therapeutics (NASDAQ:AXSM) -...
this to sayaxsome therapeutics12analysts
https://www.fool.com/earnings/call-transcripts/2024/05/06/axsome-therapeutics-axsm-q1-2024-earnings-call-tra/
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript | The Motley Fool
May 6, 2024 - AXSM earnings call for the period ending March 31, 2024.
earnings call transcriptaxsome therapeuticsaxsmq12024
https://www.benzinga.com/short-sellers/22/03/26379605/peering-into-axsome-therapeutics-incs-recent-short-interest
Peering Into Axsome Therapeutics Inc's Recent Short Interest - Axsome Therapeutics (NASDAQ:AXSM) -...
Mar 30, 2022 - Axsome Therapeutics Inc's (NASDAQ:AXSM) short percent of float has risen 15.16% since its last report. The company recently reported that it has 4.42 million...
axsome therapeuticsshort interestpeeringinc
https://www.macrotrends.net/stocks/charts/AXSM/axsome-therapeutics/operating-margin
Axsome Therapeutics Operating Margin 2014-2026 | AXSM | MacroTrends
Current and historical operating margin for Axsome Therapeutics (AXSM) over the last 10 years. The current operating profit margin for Axsome Therapeutics as...
axsome therapeuticsoperating margin20142026axsm
https://www.home.saxo/fr-fr/markets/stocks/axsm-xnas
Axsome Therapeutics Inc. action | Saxo Banque
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company.
axsome therapeuticsincactionsaxobanque
https://www.macrotrends.net/stocks/charts/AXSM/axsome-therapeutics/cash-flow-statement
Axsome Therapeutics Cash Flow Statement 2013-2026 | AXSM | MacroTrends
Ten years of annual cash flow statements for Axsome Therapeutics (AXSM). The cash flow statement is a summary of the cash inflows and outflows for a business...
cash flow statementaxsome therapeutics20132026axsm
https://finviz.com/news/341604/axsome-therapeutics-acquires-selective-pde10a-inhibitor-balipodect-for-the-treatment-of-schizophrenia-and-other-neuropsychiatric-conditions
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of...
Stock screener for investors and traders, financial visualizations.
axsome therapeuticspde10a inhibitoracquiresselective
https://www.fool.com/investing/2021/04/26/why-axsome-therapeutics-stock-is-jumping-today/
Why Axsome Therapeutics Stock Is Jumping Today | The Motley Fool
Apr 26, 2021 - The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.
axsome therapeuticsstockjumpingtodaymotley
https://www.biospace.com/axsome-therapeutics-reports-third-quarter-2020-financial-results-and-provides-business-update
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update -...
Nov 5, 2020 - COMET Phase 3 long-term safety trial of AXS-05 in MDD, and MOVEMENT Phase 3 long-term safety trial of AXS-07 in migraine completed NDA submission s for AXS-05...
axsome therapeuticsthird quarter
https://www.home.saxo/pl-pl/markets/stocks/axsm-xnas
Axsome Therapeutics Inc. akcja | Saxo Bank
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company.
axsome therapeuticsincakcjasaxobank
https://companiesmarketcap.com/axsome-therapeutics/pe-ratio/
Axsome Therapeutics (AXSM) - P/E ratio
Current and historical P/E ratio charts for Axsome Therapeutics
axsome therapeuticsaxsmratio
https://www.dlapiper.com/en-pt/news/2023/03/dla-piper-advises-axsome-therapeutics-in-license-agreement-with-pharmanovia
DLA Piper advises Axsome Therapeutics in license agreement with Pharmanovia for commercializing...
DLA Piper advised Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central...
dla piperaxsome therapeutics
https://www.financialcontent.com/article/gnwcq-2026-5-7-axsome-therapeutics-recognizes-mental-health-month
Axsome Therapeutics Recognizes Mental Health Month | FinancialContent
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central...
mental health monthaxsome therapeuticsrecognizes
https://www.benzinga.com/quote/AXSM/analyst-ratings
Axsome Therapeutics Analyst Ratings and Price Targets | NASDAQ:AXSM | Benzinga
Explore Axsome Therapeutics analyst ratings and price targets (NASDAQ:AXSM) on Benzinga. Stay updated on expert opinions and forecasts for AXSM stock.
axsome therapeuticsanalyst ratingsprice targetsnasdaqaxsm
https://ycharts.com/companies/AXSM/market_cap
Axsome Therapeutics Market Cap Insights | YCharts
In depth view into Axsome Therapeutics Market Cap including historical data from 2015, charts and stats.
axsome therapeuticsmarket capinsightsycharts
https://www.biospace.com/axsome-therapeutics-appoints-dr-sue-mahony-to-its-board-of-directors
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors - BioSpace
Oct 12, 2023 - Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders,...
board of directorsaxsome therapeutics
https://finviz.com/news/343074/axsome-therapeutics-to-report-first-quarter-2026-financial-results-on-may-4
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
Stock screener for investors and traders, financial visualizations.
axsome therapeuticsfirst quarter
https://www.biospace.com/axsome-therapeutics-to-present-at-upcoming-investor-conferences-feb-19-2021
Axsome Therapeutics to Present at Upcoming Investor Conferences - Feb 19, 2021 - BioSpace
Feb 22, 2021 - Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, will participate in...
axsome therapeutics
https://www.biospace.com/axsome-therapeutics-presents-data-from-gemini-phase-3-trial-of-axs-05-in-major-depressive-disorder-at-the-2020-american-society-for-clinical-psychopharmacology-annual-meeting
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder...
Jun 1, 2020 - Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that data...
https://www.pissedconsumer.com/company/axsome-therapeutics/customer-service.html
Axsome Therapeutics Customer Service Phone Number 1-866-496-2976, Email, Help Center
How to contact Axsome Therapeutics customer support at toll-free or general info phone number? Call or write an email to info@axsome.com to resolve Axsome...
customer service phone number
https://investingnews.com/axsome-therapeutics-initiates-clarity-phase-3-trial-of-solriamfetol-in-adults-with-major-depressive-disorder-with-excessive-daytime-sleepiness-symptoms/
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive...
Feb 24, 2026 - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today...
https://www.biospace.com/press-releases/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute-treatment-of-migraine
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment...
https://www.biospace.com/axsome-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-1-2021
Axsome Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021...
Feb 17, 2021 - Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it...
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/axsome-therapeutics-incs-nasdaqaxsm-shift-from-loss-to-profi-1
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - Simply Wall St News
We feel now is a pretty good time to analyse Axsome Therapeutics, Inc.'s ( NASDAQ:AXSM ) business as it appears the...